Heart failure frequently goes undetected until significant functional decline has occurred. A new JACC: Advances study evaluating the FDA-cleared Vivio System—a noninvasive estimator of LVEDP—screened over 2,000 high-risk primary care patients. Nearly 40% demonstrated elevated LVEDP, with most reporting symptomatic burden or impaired quality of life, yet none carried a prior diagnosis. Read more on implications for earlier HF identification in primary care.